Evidence map›Paper›PMID 25326395›Full record

ArticleAnnals of surgical oncology2015

Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.

Kentaro Inamura, Mai Yamauchi, Reiko Nishihara, Sun A Kim, Kosuke Mima, Yasutaka Sukawa, Tingting Li, Mika Yasunari, Xuehong Zhang, Kana Wu and 5 more

Open access · greenAbstract read
In one paragraph

Article in Annals of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Kentaro Inamura *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Mai Yamauchi *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Reiko Nishihara *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Sun A Kim *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Kosuke MimaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Yasutaka SukawaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Tingting LiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Mika YasunariDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Xuehong ZhangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA.
Kana WuDepartment of Nutrition, Harvard School of Public Health, Boston, MA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Charles S FuchsDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Curtis C Harris *Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Zhi Rong Qian *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Shuji Ogino *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Harvard University · USDana-Farber Cancer Institute · USNational Institutes of Health · USChinese PLA General Hospital · CN

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER · 2000 to 2019
$77.8M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SICINSKA, · 2007 to 2023
$33.2M
Precision Medicine of CancerZIABC011492 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HARRIS, CURTIS · 2013 to 2025
$23.2M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
Dietary And Lifestyle Determinants Of Colon Cancer Recurrence and SurvivalR01CA118553 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2007 to 2019
$4.4M
Impact of Celecoxib and Inflammation on Survival in Stage III Colon CancerR01CA169141 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2013 to 2018
$3.9M
Epigenetic Events and Colorectal Cancer EpidemiologyR01CA151993 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2010 to 2014
$2.6M
NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA55075NCI NIH HHS P01 CA87969NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA169141NCI NIH HHS U01 CA167552NCI NIH HHS UM1 CA167552
6 · The paper itself

Abstract

backgroundColorectal carcinoma (CRC) represents a group of histopathologically and molecularly heterogeneous diseases, which may contain signet-ring cell component and/or mucinous component to a varying extent under pathology assessment. However, little is known about the prognostic significance of those components, independent of various tumor molecular features.

methodsUtilizing a molecular pathological epidemiology database of 1,336 rectal and colon cancers in the Nurses' Health Study and the Health Professionals Follow-up Study, we examined patient survival according to the proportion of signet-ring cell and mucinous components in CRCs. Cox proportional hazards models were used to compute hazard ratio (HR) for mortality, adjusting for potential confounders including stage, microsatellite instability, CpG island methylator phenotype, LINE-1 methylation, and KRAS, BRAF, and PIK3CA mutations.

resultsCompared to CRC without signet-ring cell component, 1-50 % signet-ring cell component was associated with multivariate CRC-specific mortality HR of 1.40 [95 % confidence interval (CI) 1.02-1.93], and >50 % signet-ring cell component was associated with multivariate CRC-specific mortality HR of 4.53 (95 % CI 2.53-8.12) (P trend < 0.0001). Compared to CRC without mucinous component, neither 1-50 % mucinous component (multivariate HR 1.04; 95 % CI 0.81-1.33) nor >50 % mucinous component (multivariate HR 0.82; 95 % CI 0.54-1.23) was significantly associated with CRC-specific mortality (P trend < 0.57).

conclusionsEven a minor (50 % or less) signet-ring cell component in CRC was associated with higher patient mortality, independent of various tumor molecular and other clinicopathological features. In contrast, mucinous component was not associated with mortality in CRC patients.

Indexed as

Adenocarcinoma, MucinousAgedBiomarkers, TumorCarcinoma, Signet Ring CellColorectal NeoplasmsDNA MethylationFemaleFollow-Up StudiesHumansMaleMicrosatellite InstabilityMutationNeoplasm StagingPrognosisProspective StudiesProto-Oncogene Proteins B-rafBiomarkers, TumorProto-Oncogene Proteins B-rafras Proteins

Identifiers

PMID25326395
PMCPMC4346446
OpenAlexW1994320651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.